Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Biotechnology

Healthcare
$305.19 +4.49%

+$12.13 today

Market cap
$8.53B
Beta
2.75
P/E (TTM)
-25.0
EPS (TTM)
-$11.31
52W Low $37.19High $366.52

Volume 0.43M

Average 0.45M

PRAX Deferred Revenue

Payments received for goods or services the company will deliver within the next year.

Praxis Precision Medicines, Inc.NASDAQ: PRAX

Deferred Revenue · Q3 FY2026 · quarter ended Sep 2026

Deferred revenue remains negative

Q3 FY2026 deferred revenue was $0, compared with $0 a year earlier.

Context

  • Deferred revenue amounted to 0.0% of total assets at the end of Q3 FY2026, unchanged from a year earlier.
  • Deferred revenue increased in 0 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

Sources:Balance SheetText generated from reported figures; not investment advice.

Latest quarterSep 2026
$0— QoQ
Last fiscal yearDec 2025
$0— YoY
Year agoSep 2025
$0— since
Deferred Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR———
5-year CAGR——
10-year CAGR——

Deferred Revenue history

USD · from the balance sheet

Latest · FY2025
0 USD
Year-over-year change
—

Deferred Revenue vs competitors

How PRAX compares with its peers on the latest reported figures

  • PRAX's Sep 2026 deferred revenue of $0 is the 2nd highest of the 10 companies compared; the peer median is $0.
  • Deferred revenue amounts to 0.0% of total assets for PRAX, versus a peer median of 0.0%.
PRAX Competitors Peer median
Deferred Revenue for PRAX and competitors
Company Period Latest balance YoY 3-year CAGR% of assets
AVXLAnavex Life Sciences Corp.Dec 2025$805K -2.9%+22.0%0.6%
PRAXPraxis Precision Medicines, Inc.Sep 2026$0 ——0.0%
NBIXNeurocrine Biosciences, Inc.Sep 2026$0 ——0.0%
AXSMAxsome Therapeutics, Inc.Jun 2026$0 ——0.0%
XENEXenon Pharmaceuticals Inc.Sep 2026$0 ——0.0%
ACADACADIA Pharmaceuticals Inc.Sep 2026$0 ——0.0%
DNLIDenali Therapeutics Inc.Jun 2026$0 ——0.0%
SUPNSupernus Pharmaceuticals, Inc.Jun 2026$0 ——0.0%
RAPPRapport Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
NMRANeumora Therapeutics, Inc. Common StockMar 2026$0 ——0.0%
Peer median (excluding PRAX) $0-2.9%+22.0%0.0%

Competitors are the stored peer set for PRAX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Balance Sheet

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Cash & Equivalents138.7M61.62M81.3M215.37M357.33M
Short-term Investments137.21M38.87M0177.2M242M
Net Receivables00000
Inventory00000
Other Current Assets003.58M11.81M11.58M
Total Current Assets287.41M110.84M84.88M404.37M610.91M
Property, Plant & Equipment (Net)4.87M3.87M2.65M1.36M239K
Goodwill00000
Intangible Assets00000
Long-term Investments00076.96M0
Tax Assets00000
Other Non-current Assets472K416K416K416K326.76M
Total Non-current Assets5.34M4.29M3.07M78.74M327M
Total Assets292.75M115.13M87.95M483.11M937.91M
Account Payables10.78M14.67M5.82M12.53M24.63M
Short-term Debt00000
Tax Payables00000
Deferred Revenue02.82M1.39M00
Other Current Liabilities7.18M2.8M3.7M9.37M18.71M
Total Current Liabilities38.43M34.35M15.75M37.55M59.77M
Long-term Debt00000
Deferred Tax Liabilities00000
Deferred Revenue (Non-current)02.18M1.16M00
Other Non-current Liabilities00000
Total Non-current Liabilities3.5M4.68M2.53M110K0
Total Liabilities41.94M39.02M18.28M37.66M59.77M
Common Stock5K5K13K14K15K
Retained Earnings(316.62M)(530.64M)(653.92M)(836.74M)(1.14B)
Accumulated OCI(176K)(173K)0654K563K
Other Stockholders Equity00000
Minority Interest00000
Total Equity250.81M76.11M69.67M445.45M878.14M
Total Debt4.31M3.5M2.5M1.37M110K
Net Debt(134.39M)(58.12M)(78.81M)(214M)(357.22M)

Praxis Precision Medicines, Inc.

NASDAQ:PRAX

Intrinsic Alpha fair value

Locked

Current Price

$305.19

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.